Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation

Annals of Hematology

Volumn 84, Issue 10, 2005, Pages 675-680

  Chen, Chih Cheng ^a,b   Lee, Kuan Der ^b   Gau, Jyh Pyng ^a,c   Yu, Yuan Bin ^a,c   You, Jie Yu ^a,c   Lee, Su Chung ^a   Hsu, Hui Chi ^a,c   Chau, Wing Keung ^a,c   Ho, Chao Hung ^a,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Carboxypeptidase B; CRP; DIC; Sepsis; SOFA score; TAFI

Indexed keywords

LACTATE DEHYDROGENASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BLOOD CLOTTING TEST; BLOOD SAMPLING; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK PATIENT; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; ORGAN INJURY; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REGRESSION ANALYSIS; RISK ASSESSMENT; SCORING SYSTEM; SEPSIS;

AGED; ANTIGENS; CARBOXYPEPTIDASE U; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MICE; PLASMA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RATS; SEPSIS; SHOCK, SEPTIC;

EID: 27644514301     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1079-4     Document Type: Article

References (23)

1. Bouma BN, Marx PF, Mosnier LO, Meijers JC (2001) Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 101:329-354 10.1016/S0049-3848(00)00411-4
2. Hendriks D, Scharpe S, van Sande M, Lommaert MP (1989) Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 27:277-285 1:CAS:528:DyaL1MXksFaqtrs%3D
3. Bajzar L, Morser J, Nesheim M (1996) TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271:16603-16608 10.1074/ jbc.271.28.16603
4. Fleury V, Angles-Cano E (1991) Characterization of the binding of plasminogen to fibrin surfaces: The role of carboxy-terminal lysines. Biochemistry 30:7630-7638 10.1021/bi00244a035
5. Wang W, Boffa MB, Bajzar L et al (1998) A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 273:27176-27181 10.1074/jbc.273.42.27176
6. Sakharov DV, Plow EF, Rijken DC (1997) On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 272:14477-14482 10.1074/jbc.272.22.14477
7. Lisman T, Leebeek FW, Mosnier LO et al (2001) Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 121:131-139 1:CAS:528:DC%2BD3MXlt1ykt7Y%3D
8. van Tilburg NH, Rosendaal FR, Bertina RM (2000) Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95:2855-2859 10779431
9. Silveira A, Schatteman K, Goossens F et al (2000) Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 84:364-368 1:CAS:528:DC%2BD3MXjtVOks7Y%3D
10. Montaner J, Ribo M, Monasterio J et al (2003)Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 34:1038-1040 10.1161/01.STR.0000063139.06585.45
11. Klement P, Liao P, Bajzar L (1999) A novel approach to arterial thrombolysis. Blood 94:2735-2743 1:CAS:528:DyaK1MXmslansb8%3D
12. Sato T, Miwa T, Akatsu H et al (2000) Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 165:1053-1058 1:CAS:528:DC%2BD3cXkvFWit7g%3D
13. Kato T, Akatsu H, Sato T et al (2000) Molecular cloning and partial characterization of rat procarboxypeptidase R and carboxypeptidase N. Microbiol Immunol 44:719-728 1:CAS:528:DC%2BD3cXms1Ghs7s%3D
14. Taylor FB Jr, Toh CH, Hoots WK et al (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86:1327-1330 1:CAS:528:DC%2BD3MXosFyhsbo%3D
15. Vincent JL, Moreno R, Takala J et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707-710 1:STN:280:ByiD3c7isVM%3D
16. Wada H, Sakuragawa N, Mori Y et al (1999) Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Am J Hematol 60:273-278 10.1002/ (SICI)1096-8652(199904)60:4<273::AID-AJH4>3.0.CO;2-N
17. Watanabe R, Wada H, Watanabe Y et al (2001) Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 104:1-6 10.1016/ S0049-3848(01)00331-0
18. Levi M, de Jonge E, van der Poll T, ten Cate H (1999) Disseminated intravascular coagulation. Thromb Haemost 82:695-705 1:CAS:528:DyaK1MXnsVWmtrc%3D
19. Hambleton J, Leung LL, Levi M (2002) Coagulation: Consultative hemostasis. Hematology (Am Soc Hematol Educ Program) 335-352
20. So AK, Varisco PA, Kemkes-Matthes B et al (2003) Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 1:2510-2515 10.1111/j.1538-7836.2003.00462.x
21. Donmez A, Aksu K, Celik HA et al (2005) Thrombin activatable fibrinolysis inhibitor in Behcet's disease. Thromb Res 115:287-292 10.1016/j.thromres.2004.09.010
22. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN (1998) Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 80:829-835 1:CAS:528:DyaK1cXnsF2ju7w%3D
23. Meijers JC, Oudijk EJ, Mosnier LO et al (2000) Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 108:518-523 10.1046/j.1365-2141.2000.01890.x